|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now. In a report released on September 26, CFRA upgraded Eli Lilly and Company (NYSE:LLY) to a Buy, setting a price target of $835.00.
Eli Lilly and Company (NYSE:LLY) reported a 38% growth in its revenue for fiscal Q2 2025 to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.
The company also increased the midpoint of its 2025 full-year revenue guidance by $1.5 billion to be in the $60 billion to $62 billion range, with reported EPS guidance raised to be in the range of $20.85 to $22.10.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 1 hour | |
| 2 hours | |
| 3 hours | |
| 3 hours | |
| 3 hours | |
| 4 hours | |
| 7 hours | |
| Oct-02 | |
| Oct-02 | |
| Oct-02 | |
| Oct-02 | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite